Who We Are
What We Offer
Oct 23, 2023
Vigil Neuroscience has dosed the first subject in a Phase I clinical trial of VG-3927 to potentially treat Alzheimer’s disease (AD).
Oct 19, 2023
Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial
Oct 11, 2023
Recruit patients faster, retain more of them, and get their outcomes data sooner
Oct 4, 2023
The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.
Oct 1, 2023
Boundless Bio has announced a collaboration with Eli Lilly for its first-in-human Phase I/II trial investigating BBI-355 in solid tumours.
Mar 18, 2023
Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.